039200.KQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 14:30):

Stats
今日成交量	220 773
平均成交量	489 261
市值	1 147.42B
EPS	KRW-279.60 ( 2024-03-18 )
下一个收益日期	( KRW0 ) 2024-05-09
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW58.95 (0.20%)

音量相关性

長: -0.21 (neutral)

短: -0.24 (neutral)

Signal:(63.232) Neutral

Oscotec Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Oscotec Inc. 相关性 - 货币/商品

-0.17
( neutral )

-0.20
( neutral )

0.01
( neutral )

0.06
( neutral )

0.30
( neutral )

0.02
( neutral )

Oscotec Inc. 财务报表

Annual	2023
营收:	KRW4.95B
毛利润:	KRW1.23B (24.85 %)
EPS:	KRW-634.86

FY	2023
营收:	KRW4.95B
毛利润:	KRW1.23B (24.85 %)
EPS:	KRW-634.86

FY	2022
营收:	KRW5.06B
毛利润:	KRW1.57B (31.04 %)
EPS:	KRW-763.19

Financial Reports:

No articles found.

Oscotec Inc.

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.